# Triumvira Immunologics

Source: https://onco.cc/companies/triumvira-immunologics/  
OnCo record `triumvira-immunologics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Triumvira Immunologics is a Texas and Ontario cell-therapy company whose T-cell antigen coupler (TAC) engages the natural T-cell receptor rather than a CAR; TAC01-CLDN18.2 targets stomach and pancreatic cancers.

## Summary

Triumvira Immunologics, with operations in Austin and Hamilton, Ontario, develops T-cell antigen coupler therapies in which an antigen-binding domain is coupled to the endogenous T-cell receptor complex, aiming for the potency of CAR-T with less toxicity. TAC01-HER2 was its first solid tumour programme and TAC01-CLDN18.2 targets Claudin 18.2 in gastric, gastro-oesophageal junction and pancreatic cancers in a phase 1/2 trial.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Triumvira Immunologics, Inc.
- Tags: drug-maker
- HQ: Austin, Texas
- Type: cell-therapy
- Website: https://www.triumvira.com/

## Sources

- Official website: https://www.triumvira.com/

## Connected records

- drugs: [TAC01-CLDN18.2](https://onco.cc/drugs/tac01-cldn18-2/)

---
JSON: https://onco.cc/api/v1/entities/triumvira-immunologics.json